Volume | 62,140 |
|
|||||
News | - | ||||||
Day High | 1.04 | Low High |
|||||
Day Low | 0.96 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Cingulate Inc | CING | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
0.96 | 0.96 | 1.04 | 1.04 | 0.91715 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
240 | 62,140 | US$ 0.9871987 | US$ 61,345 | - | 0.75 - 23.40 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
18:22:38 | formt | 454 | US$ 1.04 | USD |
Cingulate Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
974.48k | 937.00k | - | 0 | -23.54M | -25.12 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Cingulate News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CING Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.8578 | 1.04 | 0.8274 | 0.8704853 | 28,275 | 0.1822 | 21.24% |
1 Month | 1.06 | 1.10 | 0.75 | 0.9224238 | 87,453 | -0.02 | -1.89% |
3 Months | 1.30 | 1.50 | 0.75 | 1.14 | 205,175 | -0.26 | -20.00% |
6 Months | 8.454 | 12.70 | 0.75 | 5.21 | 911,812 | -7.41 | -87.70% |
1 Year | 21.40 | 23.40 | 0.75 | 7.68 | 596,946 | -20.36 | -95.14% |
3 Years | 100.00 | 103.00 | 0.75 | 19.05 | 411,048 | -98.96 | -98.96% |
5 Years | 100.00 | 103.00 | 0.75 | 19.05 | 411,048 | -98.96 | -98.96% |
Cingulate Description
Cingulate Inc is a clinical stage biopharmaceutical company utilizing its proprietary precision timed release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. |